At a time when the concern regarding the overdiagnosis and overtreatment of indolent PCa has led to intense scrutiny of the value of PSA levels as an effective screening tool,3,4 our data on the increasing risks associated with higher baseline PSA levels can be used to determine the optimal PCa screening strategy for individual patients. This evidence concerns the gene KLK3 and posterior cortical atrophy.